Tweets
RA patients with an inadequate response to adalimumab, in the presence of sufficient/high ADA drug levels, benefit 33% less from switching to another TNF inhibitor, etanercept. Data 449 RA patients in the Reade Rheumatology Registry https://t.co/uBzF8D9KpA
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
A prospective 10-year study of 1,024 older women shows that severe abdominal aortic calcification (AAC) scores were associated with ncreased fracture risk (HR 1.48 [1.15-1.91], p=0.002; not fully indicated by predictors of bone structure. https://t.co/NVbo9eHcYF
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
Observational study of 124 gouty patients with high cholesterol & triglycerides treated with ULT (febuxostat, allopurinol, benzbromarone) showed that ULT significantly lowered SUA and lipid levels too. https://t.co/JSdh3TRTX3
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
NHANES analysis shows that higher serum uric acid (SUA) levels had a greater risk of coronary heart disease and stroke mortality (mainly women >50 years); but there was no link between SUA and all-cause and cancer mortality. https://t.co/UGNSiKsjQl
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
The War on RA - is being fought daily by rheumatologists - Change, Innovation and Discovery will be driven by Rheumatologists if we are to win this war. This is the 2nd of a series on the immense challenge of #RA today. We need you! https://t.co/7vOzRvvuVi
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
Cohort study shows ACE inhib. in Systemic Sclerosis at Dx was assoc w/ increased risk for Scleroderma Renal Crisis (SRC). Military System EHR study of 31 SRC to 332 non-SRC & found ACEi assoc w/ SRC (OR 4.1; CI 1.6–10.2) only in presence of proteinuria https://t.co/cMsheXrmRY
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
Is tea consumption associated with a risk of fractures? A metanalysis of 16 studies, 772,707 participants, high (compared to low) tea consumption was associated a lower fracture risk - RR 0.86 (0.78–0.94). https://t.co/24XYyUArS9
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
Billion dollar companies (J&J, Pfizer) legally sparing over Billion dollar drugs! FTC is investigating Remicade contracting practices. Pfizer (for Inflectra) asserts J&J violated antitrust laws, anticompetitive practices aimed to block Inflectra sales https://t.co/3yk4AcM5ZW
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
FDA will review to Genentechs application for Rituxan use in pediatric (age >2yrs) granulomatosis with polyangiitis & microscopic polyangiitis. If approved, this would be the 1st pediatric indication for RTX; data based on ths phase IIa PePRS study https://t.co/rRFiyQNKca
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
Testosterone replacement therapy Increases the risk of CV events (MI/CVA/TIA). Study of 15,401 men, >45 yrs old, w/ low testosterone & no evidence of hypogonadotropic or testicular dz (1995-2017). HR 1.21; CI 1.0-1.46), highest in the 1st 2yrs https://t.co/nNXyFIo1EH
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a negative opinion on Application for romosozumab (Evenity) for the treatment of severe osteoporosis (by Amgen & UCB); an appeal is planned https://t.co/EVjxuBQdF0
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
Im starting a War on RA. I need you go get mad and do your part. Read 1st of 4 part series https://t.co/sR5Z3lq8CU or watch it here https://t.co/s7CVW2dNUT
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
The FDA Arthritis Advisory Committee voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/UNlpQNJAim
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
The RheumNow Podcast is up! News, Announcements of generics/biosimilars, approvals and FDA hearings. Watch the video here>> https://t.co/3tW7uRivgQ or listen to the podcast on iTunes>> https://t.co/q2bscJkIhs
Dr. John Cush @RheumNow ( View Tweet )
7 years ago
